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Abstract 
Familial hypercholesterolemia (FH) is a common genetic disorder that is associated with 
premature cardiovascular disease (CVD). CVD is the leading cause of death and morbidity in the 
United States, and although it generally becomes clinically evident in adults, the development of 
atherosclerosis has its origins in childhood. Unfortunately, the majority of children and 
adolescents with FH go undiagnosed and untreated as signs and symptoms of CVD only develop 
after decades of hypercholesterolemia. This review of literature will discuss the importance of 
early diagnosis and treatment of FH, and how statin therapy needs to be initiated in early 
childhood before significant atherosclerosis develops.  
The significance of this problem and basis of the literature review is demonstrated by an 
outpatient clinical case involving a 24-year old male requesting to have his cholesterol levels 
checked after his father passed away suddenly from a heart attack at age 46. This case is a great 
example of how many young patients can go undiagnosed and untreated with FH because they 
are asymptomatic. This case led to the systematic search to determine that statin therapy should 
be initiated in childhood in individuals with a diagnosis of FH.  
This literature review will describe a model of care for FH focusing on the use of statin 
therapy in children and adolescents. With the availability of effective statin therapy, practitioners 
are in a place where they can improve the outcomes of this disorder by detecting and managing 
hypercholesterolemia in childhood, thereby preventing premature cardiovascular disease.  
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Significance of Initiating Statin Therapy in Children and Adolescents 
Familial hypercholesterolemia (FH) is a common genetic disorder with a prevalence of 
1:500 in the general population (Justo, 2012). It is a disorder of low-density lipoprotein 
cholesterol (LDL-C) metabolism, which is coupled with the onset of vascular changes associated 
with cardiovascular disease (CVD) in childhood (Wiegman et al., 2015). Practitioners must be 
vigilant when taking a patient’s family history with regard to early CVD. Thus, when patients 
with early CVD are assessed and treated, all family members, including children under 10 years 
of age, must be investigated. Because the atherosclerotic disease process associated with FH 
begins in childhood, practitioners should strongly consider pharmacological treatment with statin 
therapy in this population. Therefore, once affected children are identified, a plan of care 
including lifestyle changes and statin therapy should be initiated.  
Currently, there is broad consensus that statin therapy is the treatment of choice in 
children diagnosed with FH, and it should be commenced by 10 years of age. Statin therapy may 
also be indicated in children with FH aged 8 or 9 years with a family history of premature CVD, 
additional CVD risk factors and LDL-C persistently greater than 190 mg/dL after six months of 
non-pharmacological treatment such as diet and lifestyle changes (Braamskamp, Wiegman, & 
Wijburg, 2012). According to Justo 2012, the initial therapeutic goal with statin therapy is to 
lower serum LDL-C levels to values less than 130 mg/dL. 
Statins are the preferred agent for treating FH in childhood as they are safe and effective 
in all age groups. They act by inhibiting cholesterol synthesis, which in turn generates an 
increase in the number of LDL receptors and results in increased clearance of LDL-C from the 
circulation (Hardcastle et al., 2015). Several randomized controlled trials have shown clinically  
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significant reduction in both total and LDL-C in children treated with statin therapy (Justo, 
2012). According to Justo (2012), a 2010 Cochrane review estimated the difference in LDL-C 
reduction was -26.5% in children treated with statin therapy.  
To demonstrate, the case scenario presented in the following section signifies the 
importance of diagnosis and treatment of FH in early childhood and adolescence. The case 
scenario involves a 24-year old male presenting to the clinic requesting to have his cholesterol 
levels checked due to a family history of premature cardiovascular disease. His father had 
recently passed away from a heart attack while shoveling snow at the age of 46. In addition, the 
patient’s family history included a brother with known high cholesterol. The patient was 
asymptomatic, but in addition to his family history of premature CVD, he had other risk factors 
for heart disease such as an elevated BMI, heavy alcohol use, diet high in cholesterol and 
insufficient aerobic exercise. His fasting lipid panel verified the diagnosis of FH and he was 
started on high-intensity statin therapy with the goal of preventing an early adverse 
cardiovascular event. The case is discussed in detail in the following section. 
Case Report 
 For the purpose of anonymity, the patient in this case report will be called Brad.  
Brad is a 24-year old male who presents to the clinic requesting to have his cholesterol levels 
checked due to a family history of high cholesterol and premature CVD. His mother encouraged 
him to get his cholesterol levels checked after the recent passing of his father. Brad’s father 
recently passed away at the age of 46 from a heart attack while shoveling snow. In addition, his 
brother has hyperlipidemia and is on cholesterol-lowering therapy. His mother has no known  
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medical problems and Brad is otherwise feeling healthy.  The entire history was obtained from 
the patient during the visit. 
History 
Brad has a history of allergic rhinitis for which he uses Zyrtec as needed. He has no other 
known medical history and does not take any prescription medications. His past surgical history 
includes a tonsillectomy with adenoidectomy at age four. He is currently employed as an 
emergency medical technician (EMT) and works 12-hour shifts with the ambulance crew. Due to 
the nature of his shift work, Brad admits to eating an unhealthy diet consisting of fast food about 
four to five times per week. He lifts weights an average of four to five days per week but does 
not take part in any high-intensity cardio exercise. He denies any smoking history or use of 
smokeless tobacco, but he does admit to drinking alcohol socially one to two weekends per 
month in which he consumes five to six drinks. In addition, he reports drinking two beers each 
evening at home. 
Review of Systems 
During the exam, a complete review of systems was completed. Brad reports some 
“bumps” on his left elbow and left knee that are not bothersome. The remaining systems were 
reviewed with no indication of any abnormalities.  Brad denies any symptoms of fatigue, chest 
pain, shortness of breath, dizziness, palpitations or visual disturbances. He is not having any 
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Physical Exam and Diagnostic Studies 
 A focused physical exam was completed with the following findings. Vital signs 
revealed a blood pressure of 110/54 mmHg, pulse 62 beats per minute, temperature 32.1 degrees 
Celsius, weight of 200 pounds, and height of 6 foot 1 inch. The vital signs were normal with the 
exception of his BMI which is elevated 26.4. According to the National Heart, Lung, and Blood 
Institute 2016, he is overweight. The physical examination findings were unremarkable. Heart 
sounds were S1, S2 with regular rate and rhythm. Lung sounds were clear throughout lung fields. 
Pulses were 2+ in all four extremities. Carotid pulses were 2+ bilaterally without bruits. The skin 
on his left elbow and left knee appears normal in color, texture and appearance.  
Due to the patient’s family history and CVD risk factors, the diagnostic studies done 
included lab testing consisting of a fasting lipid panel and a comprehensive metabolic panel 
(CMP). The CMP revealed a normal blood glucose level of 86 mg/dL ruling out Diabetes 
Mellitus, and normal liver enzymes indicating healthy liver function. If statin therapy is 
anticipated, it is necessary to have normal liver function prior to starting the medication.  
Furthermore, the liver enzymes were relevant due to the patient’s report of above moderate 
alcohol use. All other values within the CMP were within normal limits. On the contrary, the 
fasting lipid panel revealed a total cholesterol level of 310 mg/dL, triglycerides 140 mg/dL, HDL 
60 mg/dL and LDL 209 mg/dL, indicative of hypercholesterolemia.  
Management of Care 
Due to Brad’s family history of hyperlipidemia and premature CVD-related death, and 
his own elevated total cholesterol level with a LDL cholesterol greater than 190 mg/dL, he was 
diagnosed with familial hypercholesterolemia. Although Brad did not have clinical evidence of  
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atherosclerotic cardiovascular disease, his risk factors, family history and LDL level made it 
appropriate to treat him with high intensity statin therapy. Under those circumstances, he was 
placed on Atorvastatin 40mg by mouth daily. He was educated on the side effects of the 
medication, including commonly occurring myalgia’s.  
Unfortunately, Brad is at high risk for cardiovascular disease based on his LDL-
cholesterol alone. Therefore, in addition to the high intensity statin therapy, he was educated on 
non-pharmacological treatment such as diet and lifestyle changes. He was educated on weight 
loss and dietary reduction in total and saturated fat. He was also encouraged to increase his 
intake of dietary fiber, complex carbohydrates and unsaturated fats. Lastly, he was encouraged to 
engage in aerobic exercise with a goal to reach his target heart rate of 100-170 beats per minute, 
and maintain that heart rate for 30 minutes five days per week.  
He will follow up in three months as per current guidelines to repeat a fasting lipid panel 
and recheck his liver function tests after the initiation of statin therapy. If indicated, his 
Atorvastatin may be increased to 80mg by mouth daily. His skin complaints can be reassessed at 
his follow up visit if they are still an issue. Brad verbalized understanding of the management 
plan and will schedule a three-month follow up visit. He is encouraged to call or come back to 
the clinic in the meantime with any questions or concerns. 
Brad’s case study demonstrates the opportunity for early diagnosis and treatment of 
asymptomatic patients with FH, which is essential in preventing premature adverse 
cardiovascular outcomes. For this reason, healthcare providers need to be vigilant when 
assessing patient’s CVD risk factors and family history. Routine wellness visits warrant an 
opportunity to screen, diagnose, educate and prevent unwanted complications. If Brad had not  
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presented to the clinic requesting screening, he may have ended up with premature adverse 
cardiovascular outcomes such as stroke, myocardial infarction, peripheral vascular disease and 
much more. Thus, it is the responsibility of the healthcare provider to screen every patient, 
including children and adolescents, for early CVD risk factors with each visit to ensure statin 
therapy is initiated at an optimal time if indicated.     
Search Strategies 
In order to find evidence to support the use of statin therapy in children and adolescents 
with FH, an online search was conducted using the University of North Dakota Harley French 
Library website. Two different search engines were utilized to conduct the research, PubMed and 
CINAHL.  
The first search engine utilized was CINAHL, which stands for the Cumulative Index to 
Nursing and Allied Health Literature.  CINAHL headings were used to concentrate the search. 
The first headings searched were “familial hypercholesterolemia” AND “statin therapy” and 
“children”. This search yielded nine articles.  Following this, the English language limit was 
added, still yielding nine articles. Titles were scanned for relevance and six articles were 
reviewed in detail.  Five were found to be relevant to the search topic. 
 Next, another search using “familial hyperlipidemia” AND “treatment” AND “children” 
yielded 17 articles.  Results were further limited to English language and year which resulted in 
nine articles. Eight of the articles were thoroughly reviewed and five were found relevant to the 
clinical question. Lastly, a review of reference sections of each relevant article yielded one 
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Literature Review  
FH is the most common and serious disorder of lipid metabolism that leads to premature 
coronary heart disease (Martin, Coakley, Forbes, Sullivan & Watts, 2013). Worldwide, one baby 
is born with FH every minute (Wiegman et al., 2015). Children with FH have markedly elevated 
plasma levels of LDL cholesterol from the time of birth, which in turn strongly predisposes them 
to progressive atherosclerosis throughout childhood, and premature CVD in adulthood.  
The prevalence of FH is approximately 1 in 500, but the majority of children and 
adolescents with FH are undiagnosed as signs and symptoms only develop after decades of 
hypercholesterolemia (Braamskamp et al., 2012). FH left untreated results in fatal coronary heart 
disease in 50% of males and 20% of females by 60 years of age (Martin et al., 2013). According 
to Martin et al., 2013, statins reduce LDL-C levels by up to 50%, and are appropriate to use in 
boys after 10 years of age and in girls after menarche. Therefore, if FH is diagnosed and treated 
early in childhood, these individuals can have a normal life expectancy. 
FH is diagnosed based on certain criteria including an elevated LDL-C level plus a family 
history of premature CVD, and/or a genetic diagnosis of FH from DNA testing (Wiegman et al., 
2015). Unfortunately, FH continues to be underdiagnosed and undertreated nationwide as 
screening and treatment are not consistently implemented. According to Hardcastle et al. (2015), 
evidence has proven that exposure to moderate hypercholesterolemia increases the long-term risk 
of having an adverse cardiovascular outcome. And, given the lifelong benefit of low LDL-C 
levels, there is a vital need to identify and treat children with FH at an early age to maximize the 
therapeutic benefit of statin therapy. Not to mention, statins are safe and effective in lowering 
LDL-C in children, restoring endothelial function, and regressing the thickening of the vessel 
walls at a young age (Wiegman et al., 2015). 
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Unfortunately, in patients with FH and increased LDL-C levels, a diet alone is generally 
insufficient (Kools, Kennedy & Engler, 2008). Therefore, if cholesterol levels are not 
significantly reduced after six months of lifestyle modification, pharmacological therapy should 
be considered. The National Heart, Lung and Blood Institute (NHLBI 2016), recommends that 
statin therapy should be an adjunct to diet to lower LDL-C levels in adolescent boys and 
postmenarchal girls ages 10-18 with an LDL-C greater than 190 mg/dL, or LDL-C greater than 
160 mg/dL with family history of premature CVD and two or more risk factors for CVD. Risk 
factors for CVD include, but are not limited to: hypertension, cigarette smoking, body mass 
index (BMI) greater than the 97th percentile, diabetes and kidney disease (Muir, George, & 
Whitehead, 2012). For children aged 8 or 9 years with LDL-C greater than 190 mg/dL after six 
months of diet, together with a positive family history or additional risk factors, statin therapy 
may also be initiated (NHLBI, 2016). The NHLBI (2016), recommends the initial therapeutic 
goal for children placed on statin therapy, is to lower serum LDL-C levels to values less than 130 
mg/dL. Whereas, according to Martin et al., (2013), an ideal LDL-C level is less than 110 
mg/dL. 
Indeed, statin therapy is the foundation of FH management. According to Wiegman 
(2014), Simvastatin, Lovastatin, Atorvastatin, Pravastatin, Fluvastatin and Rosuvastatin are 
approved in the United States (US) for use in children with FH. In fact, in the US these 
medications are approved from age 10 years. For children aged 8-10 years, Pravastatin 20 mg is 
the only drug approved by the US Food and Drug Administration (FDA). It is important to 
realize that the short-term efficacy and safety of these statins, including during puberty, has been 
confirmed. Braamskamp et al. (2012), found that several clinical trials have proven that no  
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significant differences regarding adverse events were reported between statin-treated and 
placebo-treated children. Moreover, there were no differences reported in growth or sexual 
development or in laboratory results such as liver enzymes or creatinine kinase (CK) levels. 
Upon beginning therapy, the choice of a particular statin is a matter of preference. Martin 
et al. (2013) mentions that Pravastatin, Fluvastatin and Simvastatin are all short acting and are 
best taken at bedtime, as most endogenous cholesterol is produced overnight. Whereas, 
Atorvastatin and Rosuvastatin are more potent statins with a longer duration of action so they 
can be taken at any time of day, but their use should be reserved for more severe forms of FH 
(Martin et al., 2013). Treatment should be initiated at the lowest recommended dose given once 
daily, and titrated up according to the LDL-C lowering response and tolerability.  Most of the 
reduction in LDL-C occurs at lower doses, with increased doses yielding small reductions in 
LDL-C and increasing the risk of long-term side effects due to greater medication exposure 
(Vuorio, 2014). Although there is no evidence supporting an absolute target LDL-C in children 
with FH, many guidelines recommend a target LDL-C level of less than 130 mg/dL from age 10 
years, or a 50% reduction in pre-treatment LDL-C levels for children 8-10 years of age 
(Wiegman, 2015).  
It is important to note that adverse effects can occur with statin use. Therefore, it is 
critical to inform patients of potential adverse reactions and monitor them closley. McCrindle et 
al. (2007) suggests that prior to initiating statin therapy, healthcare providers should measure a 
baseline CK level and liver enzymes, including an aspartate transaminase (AST) and alanine 
transaminase (ALT) level. And, inform patients of adverse reactions that include elevated liver 
enzymes, CK levels and myopathy (muscle cramps and/or weakness). On rare occasion,  
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myopathy can progress to rhabdomyolysis.  For this reason, instruct patients to report all adverse 
effects, including myopathy immediately. If myopathy is present, the statin should be stopped 
and the CK level assessed. According to McCrindle et al. (2007), if the CK level is 10 times 
above the upper limit of normal, consider it worrisome. However, CK levels can be increased in 
children who are actively participating in contact sports, so elevated CK levels shouldn’t 
automatically be attributed to statin use. Then, repeat the CK approximately two weeks after 
stopping therapy, if it has returned to normal, the same statin may be restarted at a lower dose or 
a new statin can be trialed (McCrindle et al., 2007). Likewise, the worrisome threshold for ALT 
and AST is three times above the upper limit of normal (McCrindle et al., 2007). If abnormalities 
in the liver enzymes arise, stop the medication, recheck the levels in two weeks, and restart the 
same statin at a lower dose or a new statin if the levels have returned to normal. 
As a matter of fact, recommendations for monitoring the safety and tolerability of statin 
therapy in pediatric patients with FH are similar to those in adults. After one month of statin 
therapy with no adverse drug reactions, measure a fasting lipid profile, CK, ALT and AST and 
compare results to baseline values (McCrindle et al., 2007). If target LDL levels are achieved 
and there are no laboratory abnormalities, continue statin therapy and recheck in eight weeks and 
then every three to six months (McCrindle et al., 2007). If target LDL levels are not achieved 
with the starting dose, double the dose and repeat the blood work in four weeks. Continue to 
titrate up to the maximum recommended dose until target LDL levels are achieved. In addition to 
laboratory values, monitor growth, sexual maturation and Tanner staging.  
 Moreover, adolescent females must be warned about the contraindication of statins in 
pregnancy and should consequently be counselled to suspend therapy when contemplating  
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pregnancy. According to Wiegman et al. (2015), statins should be discontinued three months 
before planned conception and during pregnancy and lactation. However, women who become 
pregnant accidentally while taking a statin should be reassured that the likelihood of fetal 
complications is small (Wiegman et al., 2015). Referral to an adolescent medicine or 
gynecologic specialist is more than appropriate. 
All things considered, statin treatment is an efficient lipid-lowering therapy in children 
and adolescents with FH. Vuorio et al. (2104) found that several meta-analyses and a Cochrane 
systematic review have confirmed that statins are both effective and safe in the short to medium 
term in children and adolescents, but the longer term safety of these medications in this age 
group remains to be established. The average follow-up time in clinical trials was only six 
months, and the longest follow up was for two years (Vuorio et al., 2014). For that reason, large 
long-term randomized controlled trials are needed to establish the long-term safety issues of 
statins. 
The most common adverse effects that have been reported in children on statin therapy 
are: gastrointestinal symptoms including abdominal pain, constipation and diarrhea, skin rashes, 
sleep disturbance and headaches (Martin et al., 2013). In most cases, Martin et al. (2013) reports 
that side effects occur in the early phases of treatment and resolve spontaneously without 
needing to change the medication. Furthermore, it is unusual to develop side effects to statin 
therapy if it has been tolerated for months or years. As a matter of fact, there is no evidence to 
support the development of tolerance, dependence or toxicity after prolonged use.  
 To emphasize, Vuorio (2014) found that several meta-analyses and a Cochrane 
systematic review have reported on statin therapy in children with FH. And, in terms of lipid  
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lowering, these drugs are as effective in children as in adults, with mean LDL-C reductions of 
23% to 40% on average depending on the dose and type of statin prescribed. Not to mention, 
adverse effects do not appear to be increased in children over those noted in clinical studies in 
adults (Vuorio, 2014). Nonetheless, an issue of particular concern is whether statin treatment has 
any potential impact on development. Kusters et al. (2014) found clinical trials that have spanned 
the age range of pubertal development with no impact on sexual or physical maturation. In 
addition, only rarely was there the risk of a high increase in liver and muscle enzymes and this 
risk was similar in both the statin and the control groups. There were no clinically important 
differences in the risk of myopathy or clinical adverse events between the groups (Kusters et al., 
2014). Another key point is that families reported no problems with quality of life or anxiety due 
to drug therapy. In fact, children reported that taking medication made them feel safer (Vuorio, 
2014).  
Overall, several clinical studies have indicated the beneficial effect of statins on LDL-C 
levels and markers of premature atherosclerosis in children with FH, as well as their safety. 
Future clinical studies should address the long-term safety and tolerability of statins as well as 
the reduction in adverse cardiovascular outcomes in adulthood in patients with FH. Until then, 
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coronary heart disease in 50% of males and 20% of females by 60 years of age (Martin et 
al., 2013). 
• Statin therapy is the foundation of FH management. They have proven to reduce low-
density lipoprotein cholesterol levels by up to 50% and are appropriate to use in boys 
after 10 years of age and in girls after menarche (Martin et al., 2013). And, if FH is 
diagnosed and treated early in childhood, these individuals can have a normal life 
expectancy. 
• Treatment with statins should be initiated at the lowest recommended dose given once 
daily, and titrated up according to the LDL-C lowering response and tolerability. Routine 
monitoring of laboratory values, growth, sexual maturation and side effects is crucial. 
• Clinical trials have proven that statin treatment has no impact on sexual or physical 
maturation. And, there have been no clinically significant differences in the risk of 
myopathy or adverse events between the statin and control groups.  
• Statins are both effective and safe in the short to medium term in children and 
adolescents, however, large long-term randomized controlled trials are needed to 
establish the long-term safety issues of statins. Likewise, further studies are needed to 
determine the optimal age of initiation of statin treatment in children. 
Practice Recommendations 
Practitioners must be vigilant when taking a family history with regard to early CVD. 
Because the atherosclerotic disease process associated with FH begins in childhood, practitioners 
should strongly consider pharmacological treatment with statin therapy in this population. So,  
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once affected children are identified, a plan of care including lifestyle changes and statin therapy 
should be initiated.  
The NHLBI (2016) has recently published guidelines on the approach to CVD in 
childhood. According to NHLBI (2016), the initial step in treatment of FH is lifestyle 
modification, including dietary changes with limited saturated fat cholesterol intake. If lifestyle 
adjustment alone fails to sufficiently lower serum LDL-C levels, which is very likely in children 
with FH, statin therapy can be initiated in children as young as age 8 years or older. Once 
treatment is started, it should be continued for life; however, long-term follow-up studies on 
safety are lacking.  
It is important to realize that optimal health care management for children with FH needs 
to be provided through a multidisciplinary approach, including primary care and specialty 
pediatric care providers. The decision regarding when to initiate drug therapy to reduce LDL 
cholesterol levels in children and adolescents is a balance between the benefits of starting 
treatment before the onset of significant disease versus the risks of therapy. 
The age of the child, the family history of CVD, the level of LDL cholesterol and the 
views of the family are all critical to the decision-making process. Children and adolescents 
being treated with statins should be carefully monitored and followed up by their healthcare 
providers into adulthood.  
Conclusion 
In conclusion, there is strong evidence that the process of atherosclerosis originates in 
childhood and that risk factors such as hypercholesterolemia are related to subsequent CVD. In  
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order to prevent CVD later in life, identification of children with FH should start at an early age.  
Encouraging results have been obtained from clinical trials of statins in children and adolescents  
with familial hypercholesterolemia; however, long-term safety issues remain of concern, as does 
impact on clinical disease into adulthood. Further studies are needed to determine the optimal 
age of initiation of statin treatment in children with FH, as well as address the long-term safety 
and tolerability of statins and reduction of CVD in adulthood. Until then, the benefits and risks of 

















STATINS IN CHILDREN DIAGNOSED WITH FAMILIAL HYPERCHOLESTEROLEMIA 
 
References 
Braamskamp, M. M., Wiegman, A., & Wijburg, F. A. (2012). Drug Therapy of 
Hypercholesterolemia in Children and Adolescents. Drugs, 72(6), 759-772 14p. 
doi:10.2165/11632810-000000000-00000 
Hardcastle, S., Legge, E., Laundy, C., Egan, S., French, R., Watts, G., & Hagger, M. (2015). 
Patients' Perceptions and Experiences of Familial Hypercholesterolemia, Cascade 
Genetic Screening and Treatment. International Journal of Behavioral Medicine, 22(1), 
92-100 9p. doi:10.1007/s12529-014-9402-x 
Justo, R. (2012). Management of familial hypercholesterolemia in children and adolescents. 
Journal of Pediatrics & Child Health, 48(2), E53-8 1p. doi:10.1111/j.1440 
1754.2011.02206.x 
Kools, S., Kennedy, C., & Engler, M. (2008). Pediatric hyperlipidemia: child and adolescent  
disease understandings and perceptions about dietary adherence. Journal for Specialists 
in Pediatric Nursing, 13(3), 168-179 12p. 
Kusters, D. M., Avis, H. J., de Groot, E., Wijburg, F. A., Kastelein, J. P., Wiegman, A., & 
Hutten, B. A. (2014). Ten-year follow-up after initiation of statin therapy in children with  
familial hypercholesterolemia. JAMA: Journal of The American Medical Association,  
312(10), 1055-1057 3p. doi:10.1001/jama.2014.8892 
Martin, A. C., Coakley, J., Forbes, D. A., Sullivan, D. R., & Watts, G. F. (2013). Familial 
hypercholesterolemia in children and adolescents: A new pediatric model of care. 
Journal of Pediatrics & Child Health, 49(4), E263-72 1p. doi:10.1111/jpc.12036 
McCrindle, B., Urbina, E., Dennison, B., Jacobson, M., Steinberger, J., Rocchini, A., & ... 
20 
STATINS IN CHILDREN DIAGNOSED WITH FAMILIAL HYPERCHOLESTEROLEMIA 
 
Daniels, S. (2007). Drug therapy of high-risk lipid abnormalities in children and 
adolescents: a scientific statement from the American Heart Association Atherosclerosis, 
Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in 
the Young, with the Council on Cardiovascular Nursing. Circulation, 115(14), 1948-1967 
20p.  
Muir, L. A., George, P. M., & Whitehead, L. (2012). Using the experiences of people with 
familial hypercholesterolemia to help reduce the risk of cardiovascular disease: a 
qualitative systematic review. Journal of Advanced Nursing, 68(9), 1920-1932 13p. 
doi:10.1111/j.1365-2648.2012.05957.x 
National Heart, Lung, and Blood Institute. (2016). Calculate your body mass index. Retrieved 
from http://www.nhlbi.nih.gov/health/educational/lose_wt/BMI/bmicalc.htm 
National Heart, Lung, and Blood Institute. (2016). Lipids and Lipoproteins. Retrieved from 
http://www.nhlbi.nih.gov/health-pro/guidelines/current/cardiovascular-health-pediatric-
guidelines/full-report-chapter-9 
Rodenburg, J., Vissers, M., Wiegman, A., van Trotsenburg, A., van der Graaf, A., de Groot, E.,        
& ... Hutten, B. (2007). Statin treatment in children with familial hypercholesterolemia: 
the younger, the better. Circulation, 116(6), 664-668 5p.  
Vuorio, A., Kuoppala, J., Kovanen, P., Humphries, S., Strandberg, T., Tonstad, S., & Gylling, H. 
(2014). Statins for children with familial hypercholesterolemia. Cochrane Database Of 
Systematic Reviews, (7), N.PAG-N.PAG 1p.  
Wiegman, A., Gidding, S.S, Watts, G.F., Chapman, J.M., Ginsberg, H.N., Cuchel, M., … 
Wiklund, O. (2015). Familial hypercholesterolemia in children and adolescents: gaining 
21 
STATINS IN CHILDREN DIAGNOSED WITH FAMILIAL HYPERCHOLESTEROLEMIA 
 
decades of life by optimizing detection and treatment. European Heart Journal. doi: 
10.1093/eurheartj/ehv157  
 
